You are viewing: Asia Pacific Immune Repertoire Sequencing Market analysis

The Asia Pacific Immune Repertoire Sequencing Market was valued at $49.5 Million in 2025 and projected to reach to $81.1 Million by 2030, representing a compound annual growth rate of 10.4%. The Asia Pacific immune repertoire sequencing market is positioned for sustained growth through 2030, expanding from $49.5 million to $81.1 million.

Asia Pacific Immune Repertoire Sequencing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Asia Pacific Immune Repertoire Sequencing Market Trends and Insights

  • Asia Pacific's growth trajectory reflects increasing adoption of advanced sequencing technologies in immunology research, cancer diagnostics, and personalized medicine across the region.
  • The market in Asia Pacific is driven by rising healthcare investments, expanding biotechnology sectors in China, India, and Japan, and growing demand for precision diagnostics. Asia Pacific's 10.4% compound annual growth rate outpaces global benchmarks, underscoring the region's strategic importance in immune repertoire sequencing innovation.
  • Key markets within Asia Pacific are leveraging next-generation sequencing platforms to enhance T-cell and B-cell profiling capabilities.
  • Between 2025 and 2030, Asia Pacific is expected to capture significant market share through increased clinical adoption, academic research funding, and collaborations between regional biotech firms and global leaders. The competitive landscape in Asia Pacific features both established international players and emerging regional innovators.
  • Asia Pacific's favorable regulatory environment and cost-effective manufacturing capabilities position the region as a critical hub for immune repertoire sequencing technology development and commercialization..

Key Market Statistics

  • CAGR (2025-2030) 10.4% CAGR
  • Market Size, 2025 ~USD 49.5 Million
  • Forecast, 2030 ~USD 81.1 Million
  • Geography Asia Pacific

Asia Pacific Immune Repertoire Sequencing Market Overview

Rapid Market Expansion :

Asia Pacific immune repertoire sequencing market is growing at 10.4% CAGR, outpacing the global rate of 9.6%, driven by increasing investments in genomic research infrastructure and immunology applications across the region.

China's Market Leadership :

China dominates the Asia Pacific market with $34.5 million in 2025, reflecting strong government support for precision medicine initiatives and expanding biopharmaceutical R&D capabilities in immunological research.

Cancer Diagnostics & Personalized Medicine :

Growing adoption of immune repertoire sequencing in oncology and personalized medicine applications across Asia Pacific is accelerating clinical adoption, particularly in Japan, South Korea, and emerging markets like India.

Emerging Market Opportunities :

India and Southeast Asian nations represent high-growth opportunities with increasing healthcare modernization, rising cancer incidence, and growing demand for advanced diagnostic technologies in immunology research.

Asia Pacific Immune Repertoire Sequencing Market Dynamics

  • This trajectory is supported by increasing adoption of next-generation sequencing technologies in immunology research, cancer diagnostics, and vaccine development across the region.
  • Government initiatives promoting precision medicine and genomic research, combined with rising healthcare expenditure in developed and emerging economies, are key growth catalysts. Key drivers include expanding biopharmaceutical R&D activities, growing prevalence of cancer and autoimmune diseases, and increasing collaboration between academic institutions and industry players.
  • China and Japan lead market adoption, while India and other emerging markets present significant untapped potential.
  • Technological advancements in sequencing platforms and declining costs are expected to further accelerate market penetration across Asia Pacific healthcare systems..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Asia Pacific immune repertoire sequencing market valued at $49.5M in 2025, expanding to $81.1M by 2030 at 10.4% CAGR
    • Asia Pacific's growth rate exceeds global average, driven by biotech expansion in China, India, and Japan
    • Asia Pacific adoption accelerating in cancer immunotherapy, infectious disease diagnostics, and personalized medicine applications
    • Asia Pacific emerging as manufacturing and innovation hub with favorable regulatory frameworks and cost advantages

    Immune Repertoire Sequencing Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment TCR KITS (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 9.6% from 2025 to 2030
    Largest Segment ASSAY KITS & REAGENTS (Product)
    Market Size Base Year (Billions) ~USD 0.35 (2025)
    Revenue Forecast (Billions) ~USD 0.56 (2030)
    Segments Covered Product, Type

    Asia Pacific Immune Repertoire Sequencing Market Report Segmentation

    2 segment dimensions are covered across the global market.

    By Product

    • Assay Kits & Reagents
    • Instruments & Software

    By Type

    • Bcr Kits
    • Other Assay Kits & Reagents
    • Tcr Kits

    Target Audience

    • Biopharmaceutical Companies : Need Asia Pacific market data to guide R&D investments, clinical trial planning, and commercialization strategies for immune-based therapeutics and diagnostic solutions in high-growth markets.
    • Diagnostic & Sequencing Technology Providers : Require regional market intelligence to identify expansion opportunities, assess competitive positioning, and develop localized product strategies for Asia Pacific healthcare systems.
    • Healthcare Investment Firms : Seek comprehensive Asia Pacific market analysis to evaluate investment opportunities in genomics, immunology research, and precision medicine companies with strong regional growth potential.
    • Academic & Research Institutions : Need market data to understand funding landscapes, technology adoption trends, and collaboration opportunities in immune repertoire sequencing research across Asia Pacific universities and research centers.
    • Healthcare Policy & Government Agencies : Require market insights to inform precision medicine initiatives, genomic research funding, and healthcare technology adoption policies aligned with Asia Pacific regional development goals.

    Key Companies in the Asia Pacific Immune Repertoire Sequencing Market

    CompanyHQOwnershipStrongest segments
    ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    PACBIOUnited StatesPublic CompanyLong-read sequencing instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read sequencing (Onso and related consumables),
    OXFORD NANOPORE TECHNOLOGIES PLCUnited KingdomPublic CompanyPromethION (2/24/48) instruments and consumables,MinION Mk 1D and related consumables,GridION / GridION Q systems and consumables,
    10X GENOMICSUnited StatesPublic CompanyChromium single-cell instruments and consumables,Visium spatial instruments and consumables,Xenium in situ instruments and consumables,
    QIAGENNetherlandsPublic CompanySample technology consumables and instruments,Immune response and infectious-disease diagnostics,Oncology and sexual & reproductive health assays,
    AGILENT TECHNOLOGIESUnited StatesPublic CompanyLife Sciences and Diagnostics (instruments, reagents, genomics, pathology, CDMO, biomolecular analysis),Agilent CrossLab (services, consumables, software, asset management),Applied Markets (GC, MS, spectroscopy, vacuum, remarketed instruments),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and related solutions),Life Sciences (research and genomic tools),Diagnostics (clinical instruments and consumables),
    TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
    ADAPTIVE BIOTECHNOLOGIESUnited StatesPublic CompanyclonoSEQ MRD diagnostics,Life sciences research immunosequencing,Pharma and biotech drug discovery partnerships,
    PERSONALIS, INC.United StatesPublic CompanyPharma and biotech translational research / clinical trial services (ImmunoID NeXT and exome-based services),MRD and therapy monitoring (NeXT Personal, NeXT Personal Dx),Clinical tumor profiling and Dx (NeXT Dx and related tests),

    ILLUMINA, INC.

    Illumina, Inc. is a United States-based public company founded in 1998 that employs 8,625 people. The company operates in the life sciences and genomics sector.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. It is a major provider of analytical instruments, reagents, and laboratory services.

    PACBIO

    PacBio is a United States-based public company founded in 2000 with 485 employees. The company specializes in DNA sequencing technology and solutions.

    OXFORD NANOPORE TECHNOLOGIES PLC

    Oxford Nanopore Technologies PLC is a United Kingdom-based public company founded in 2005 with 1,316 employees. It develops nanopore-based DNA and RNA sequencing technologies.

    10X GENOMICS

    10X Genomics is a United States-based public company founded in 2012 with 1,178 employees. The company provides solutions for single-cell and spatial genomics analysis.

    QIAGEN

    QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees. It develops and manufactures molecular diagnostics and life sciences products.

    AGILENT TECHNOLOGIES

    Agilent Technologies is a United States-based public company founded in 1999 with 18,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees. It operates across multiple sectors including life sciences, diagnostics, and environmental solutions.

    TAKARA BIO INC.

    Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company develops and manufactures molecular biology reagents and biotechnology products.

    ADAPTIVE BIOTECHNOLOGIES

    Adaptive Biotechnologies is a United States-based public company founded in 2009 with 624 employees. The company develops immune-driven diagnostics and therapeutics using T-cell and B-cell receptor sequencing.

    PERSONALIS, INC.

    Personalis, Inc. is a United States-based public company founded in 2011 with 260 employees. The company offers precision medicine and genomic analysis services.

    Asia Pacific vs. other regions

    HowAsia Pacific compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 149.3 Million · 9.3% wtd CAGR ·
    Europe
    ~USD 99.5 Million · 9.9% wtd CAGR ·
    Latin America
    ~USD 17 Million · 8.3% wtd CAGR ·

    Countries within Asia Pacific - compare and drill down

    Country2025 size (native)
    ChinaUSD 34.5 Million
    JapanUSD 16.4 Million
    IndiaUSD 9.3 Million
    South KoreaUSD 4.7 Million
    AustraliaUSD 4.5 Million

    Country market size visualization

    China
    USD 34.5 Million
    Japan
    USD 16.4 Million
    India
    USD 9.3 Million
    South Korea
    USD 4.7 Million
    Australia
    USD 4.5 Million

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasts : Obtain precise market valuations for Asia Pacific ($49.5M in 2025) and country-level breakdowns including China, Japan, India, and Australia to support strategic planning and investment decisions.
    • Growth Opportunity Identification : Identify high-growth segments within Asia Pacific including cancer diagnostics, vaccine development, and personalized medicine applications with 10.4% CAGR outpacing global growth.
    • Competitive Landscape Intelligence : Understand market dynamics, key players, and competitive positioning specific to Asia Pacific to inform market entry strategies and partnership opportunities in this rapidly expanding region.
    • Country-Specific Market Insights : Access detailed analysis of individual Asia Pacific markets including China ($34.5M), Japan ($16.4M), and India ($9.3M) to tailor regional expansion and localization strategies.
    • Technology Adoption Trends : Gain insights into sequencing technology adoption patterns, regulatory environments, and healthcare infrastructure development across Asia Pacific to optimize product positioning and market timing.

    Frequently asked questions

    What is the current market size of immune repertoire sequencing in Asia Pacific?

    The Asia Pacific immune repertoire sequencing market is valued at $49.5 million in 2025 and is projected to grow to $81.1 million by 2030.

    What is the growth rate for immune repertoire sequencing in Asia Pacific?

    Asia Pacific's immune repertoire sequencing market is growing at a compound annual growth rate (CAGR) of 10.4% from 2025 to 2030.

    Which countries in Asia Pacific are driving market growth?

    China, India, and Japan are the primary growth drivers in Asia Pacific, supported by expanding biotechnology sectors and increased healthcare investments.

    What applications are fueling demand in the Asia Pacific market?

    Cancer immunotherapy, infectious disease diagnostics, personalized medicine, and academic immunology research are key applications driving Asia Pacific market expansion.

    Why is Asia Pacific becoming a hub for immune repertoire sequencing?

    Asia Pacific offers favorable regulatory environments, cost-effective manufacturing, growing biotech infrastructure, and increasing collaboration between regional and global innovators.

    RESEARCH METHODOLOGY

    This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global IRS market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    The market for the companies offering IRS is arrived at by secondary data available through paid and unpaid sources, analyzing the product and service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives. Secondary data was analyzed to arrive at the overall size of the global IRS market, which was validated through primary research.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global IRS market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biotechnology companies, and experts from the supply side, such as C-level and D-level executives and managers. These interviews were conducted across major regions: North America, Europe, the Asia Pacific, and the Rest of the World (including Latin America, the Middle East, and Africa). This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

    The following is a breakdown of the primary respondents:

    Immune Repertoire Sequencing Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the IRS market was estimated and validated through multiple approaches, such as the top-down and bottom-up approaches. These methods were also used extensively to estimate the size of various market subsegments.

    • The research methodology used to estimate the market size includes the following:
    • The key players in the immune repertoire sequencing market have been identified through extensive primary and secondary research.
    • The revenues generated from the immune repertoire sequencing businesses of leading players in product and service offerings were determined separately through primary and secondary research.
    • The sum of the product and service market was used to arrive at the total IRS global market size, which was further segmented into various segments.
    • All percentage shares, splits, and breakdowns for respective market segments were determined using secondary sources and verified through primary sources.  
    Immune Repertoire Sequencing Market

    Data Triangulation

    After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

    Market Definition

    Immune repertoire refers to the diverse collection of T-cell and B-cell receptors within the adaptive immune system, which enables pathogen recognition and targeted immune responses. The IRS market encompasses technologies, products, and services that analyze the diversity and functional dynamics of T-cell and B-cell receptor repertoires within the adaptive immune system.

    This market includes instruments, software, assays, kits, and reagents for immune receptor profiling, alongside presequencing, sequencing, and data analysis services that support research applications, drug discovery & development, and clinical diagnostics utilizing advanced methods such as NGS and PCR by various end users.

    Stakeholders

    • CDMOs & CROs
    • Pharmaceutical & Biopharmaceutical Companies
    • Academic & Research Institutes
    • Diagnostic Companies
    • Venture Capitalists & Investors
    • Market Research & Consulting Firms
    • Government & Regulatory Associations

    Report Objectives

    • To define, describe, and forecast the IRS market based on product, products technology, service workflow, application, product end user, service end user, and region.
    • To provide detailed information regarding the major factors influencing market growth (drivers, opportunities, and industry-specific challenges) along with the current trends
    • To strategically analyze micromarkets concerning their growth trends, prospects, and contributions to the total IRS market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the revenue of market segments with respect to six major regions: North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
    • To profile key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments in the IRS market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and R&D activities
    • To track and analyze the impact of AI/Gen AI on the IRS market
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and service excellence strategy

     

    Get the Full Immune Repertoire Sequencing Market Report

    Full forecast, segment splits, and company analysis for all Immune Repertoire Sequencing Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status